Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOXO1 | Q12778 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 11/20 | 0.33 |
| ▸ | CNR2 | P34972 | 11/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27656225 | 0.91 | FOXO1 (0.42) | FOXO1MEN1GAAKMT2APDE10A | |
| SCHEMBL1241462 | 0.88 | FOXO1 (0.46) | FOXO1MEN1GAAKMT2APDE10A | |
| SCHEMBL27656227 | 0.84 | FOXO1 (0.44) | FOXO1MEN1GAAKMT2APDE10A | |
| SCHEMBL31372321 | 0.80 | FOXO1 (0.59) | FOXO1MEN1GAAKMT2APDE10A | |
| SCHEMBL17387389 | 0.80 | FOXO1 (0.59) | FOXO1MEN1GAAKMT2APDE10A | |
| SCHEMBL18925604 | 0.79 | FOXO1 (0.51) | FOXO1MEN1GAAKMT2APDE10A | |
| SCHEMBL1244248 | 0.76 | MEN1 (0.56) | FOXO1MEN1GAAKMT2APDE10A | |
| SCHEMBL4097888 | 0.73 | FOXO1 (0.60) | FOXO1MEN1GAAKMT2AGSK3B | |
| SCHEMBL1243855 | 0.71 | FOXO1 (0.51) | FOXO1MEN1GAAKMT2AGSK3B | |
| SCHEMBL4165411 | 0.71 | MEN1 (0.52) | FOXO1MEN1GAAKMT2APDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090124617-A1 | QUINOLONE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-05-14 | — | — | US | disclosed |
| US-7488739-B2 | Quinolone derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2009-02-10 | — | — | US | disclosed |
| US-20060148806-A1 | Quinolone derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124617-A1 | QUINOLONE DERIVATIVE OR SALT THEREOF | THPO, ABL1, GMPS | FOXO1 4219/4885MEN1 2643/4885GAA 1758/4885 |
| US-20060148806-A1 | Quinolone derivative or salt thereof | THPO, ABL1, GMPS | FOXO1 4219/4885MEN1 2643/4885GAA 1758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.